Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression

Le résumé fourni par la source

Treatment-resistant depression (TRD) is defined as the failure to achieve a clinically significant improvement in major depressive disorder (MDD) despite treatment with at least two different standard antidepressants administered at adequate doses duration.1 TRD significantly impairs daily functioning and imposes a considerable economic burden in the United States. 2 Given the limited number of FDA-approved medications currently available for the treatment of TRD, 3 there remains an urgent unmet need for safer and more effective therapies.Recently, the U.S. Food and Drug Administration (FDA) granted a fast-track review designation for psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) as a treatment for MDD and TRD, highlighting the therapeutic potential of psychedelic compounds.4 In addition, 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine; 1; Figure 1A) and DMT (N,Ndimethyltryptamine; 4; Figure 2) demonstrated promise in rapidly alleviating symptoms of TRD.5-7 5-MeO-DMT is a rapidly acting atypical psychedelic that occurs naturally in various plants and in the venom of the Colorado River toad (Incilius alvarius).8

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.